3-Methyl-PCPy is an arylcyclohexylamine derivative with an unusual spectrum of pharmacological effects, acting as both a potent NMDA antagonist and also a triple reuptake inhibitor which inhibits reuptake of all three monoamine neurotransmitters serotonin, dopamine and noradrenaline. It also acts as a high affinity sigma receptor ligand, selective for the σ2 subtype. It produces both stimulant and dissociative effects in animal behavioural studies.
3-Methyl-PCPy is covered by drug analogue laws in various jurisdictions (UK, Germany, Japan, Australia etc) as a generic arylcyclohexylamine derivative, and a structural isomer of phencyclidine.
NOTE: According to the NDEWS Web Monitoring Team, led by Dr. Elan Barenholtz and Ph.D. candidate Paul Morris of the Machine Perception and Cognitive Robotics (MPCR) Lab at Florida Atlantic University, early mentions of 3-Methyl-PCPy in drug Subreddit discussions indicate the availability of an anticipated new psychoactive substance. 3-Methyl-PCPy, abbreviated 3-Me-PCPy, is an analog and structural isomer of PCP. In late May 2021, algorithmic monitoring of ~80 drug-oriented Subreddits detected the first mentions of 3-Me-PCPy on Reddit, indicating interest in the drug in anticipation of its availability through online marketplaces as a new PCP derivative.